Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) EBITDA Margin: 2022-2023

Historic EBITDA Margin for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to 29,948.00%.

  • Lexeo Therapeutics' EBITDA Margin rose 180541.00% to 29,948.00% in Q4 2023 from the same period last year, while for Dec 2023 it was 33,420.49%, marking a year-over-year change of. This contributed to the annual value of 71,851.09% for FY2024, which is 3946378.00% up from last year.
  • Latest data reveals that Lexeo Therapeutics reported EBITDA Margin of 29,948.00% as of Q4 2023, which was down 23.18% from 38,986.54% recorded in Q3 2023.
  • In the past 5 years, Lexeo Therapeutics' EBITDA Margin registered a high of 38,986.54% during Q3 2023, and its lowest value of -3,292.28% during Q3 2022.
  • Over the past 2 years, Lexeo Therapeutics' median EBITDA Margin value was 29,045.30% (recorded in 2022), while the average stood at 26,455.46%.
  • Data for Lexeo Therapeutics' EBITDA Margin shows a peak YoY soared of 4,227,882bps (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Lexeo Therapeutics' EBITDA Margin stood at 28,142.59% in 2022, then spiked by 180,541bps to 29,948.00% in 2023.
  • Its EBITDA Margin stands at 29,948.00% for Q4 2023, versus 38,986.54% for Q3 2023 and 26,367.92% for Q2 2023.